These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12495173)

  • 41. The QT interval and torsade de pointes.
    Moss AJ
    Drug Saf; 1999; 21 Suppl 1():5-10; discussion 81-7. PubMed ID: 10597863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levofloxacin-induced torsades de pointes.
    Patel PD; Afshar H; Birnbaum Y
    Tex Heart Inst J; 2010; 37(2):216-7. PubMed ID: 20401298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amiodarone and torsades de pointes in patients with advanced heart failure.
    Middlekauff HR; Stevenson WG; Saxon LA; Stevenson LW
    Am J Cardiol; 1995 Sep; 76(7):499-502. PubMed ID: 7653452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Torsades de pointes from terfenadine and sotalol given in combination.
    Feroze H; Suri R; Silverman DI
    Pacing Clin Electrophysiol; 1996 Oct; 19(10):1519-21. PubMed ID: 8904547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user.
    Atkinson D; Dunne A; Parker M
    Anaesthesia; 2007 Sep; 62(9):952-5. PubMed ID: 17697226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sotalol-induced torsades de pointes in patients with renal failure.
    Dancey D; Wulffhart Z; McEwan P
    Can J Cardiol; 1997 Jan; 13(1):55-8. PubMed ID: 9039065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.
    Barrett TD; Hennan JK; Fischbach PS; O'Neill BP; Driscoll EM; Lucchesi BR
    Br J Pharmacol; 2001 Apr; 132(7):1493-500. PubMed ID: 11264243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cesium chloride-induced torsades de pointes.
    Wiens M; Gordon W; Baulcomb D; Mattman A; Mock T; Brown R
    Can J Cardiol; 2009 Sep; 25(9):e329-31. PubMed ID: 19746253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Flecainide induced ventricular tachycardia (torsades de pointes).
    Thevenin J; Da Costa A; Roche F; Romeyer C; Messier M; Isaaz K
    Pacing Clin Electrophysiol; 2003 Sep; 26(9):1907-8. PubMed ID: 12930510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
    Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
    J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of torsades de pointes by atropine.
    Tan HL; Wilde AA; Peters RJ
    Heart; 1998 Jan; 79(1):99-100. PubMed ID: 9505930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450].
    Hrovatin E; Zardo F; Brieda M; Dametto E; Piazza R; Antonini-Canterin F; Cassin M; Meneguzzo N; Viel E; Lestuzzi C; Di Gennaro G; Nicolosi GL
    Ital Heart J Suppl; 2004 Sep; 5(9):735-40. PubMed ID: 15568612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.
    Hoehns JD; Stanford RH; Geraets DR; Skelly KS; Lee HC; Gaul BL
    Pharmacotherapy; 2001 Jul; 21(7):871-83. PubMed ID: 11444585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ['Cardiac ballet' with and without amiodarone].
    Balestra B; Hess T
    Schweiz Med Wochenschr; 1993 Jan; 123(1-2):20-5. PubMed ID: 8421775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unusual case of severe arrhythmia developed after acute intoxication with tosylchloramide.
    Lariccia V; Moraca A; Marini M; Nasti AA; Battistoni I; Amoroso S; Perna GP
    BMC Pharmacol Toxicol; 2013 Jan; 14():8. PubMed ID: 23347670
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.
    Gandhi PJ; Menezes PA; Vu HT; Rivera AL; Ramaswamy K
    Am J Health Syst Pharm; 2003 Dec; 60(23):2479-83. PubMed ID: 14686224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.